Stage II in the development of Eph/ephrin based tumor targeting reagents: Optimisation of drug efficacy and delivery

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/284418

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In the final stage of cancer, including melanoma, tumor cells gain the ability to spread, a process called metastasis. Altered communication between cancer and normal cells is one of the causes of this invasive characteristic. We have started the development of novel agents that target and modulate proteins on the cell surface that control these properties and are found in metastatic tumors. We propose to refine the targeting and killing properties of these agents for early clinical testing.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2005

Funding Scheme: NHMRC Development Grants

Funding Amount: $204,125.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Anti-cancer drugs | Cancer: mechanism of growth, invasion, metastasis | Drug design | Membrane Protein | melanoma

Related Links